This content is from: Home

Why India's Novartis ruling is not patent Armageddon

The Supreme Court’s denial of Novartis’s Glivec patent has prompted dire warnings about patent protection in India, but practitioners say that the decision was just a straightforward application of the law

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial